Obesity diminishes response to PD-1-based immunotherapies in renal cancer

BACKGROUND: Obesity is a major risk factor for renal cancer, yet our understanding of its effects on antitumor immunity and immunotherapy outcomes remains incomplete. Deciphering these associations is critical, given the growing clinical use of immune checkpoint inhibitors for metastatic disease and...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Immunother Cancer
Main Authors: Boi, Shannon K, Orlandella, Rachael M, Gibson, Justin Tyler, Turbitt, William James, Wald, Gal, Thomas, Lewis, Buchta Rosean, Claire, Norris, Katlyn E, Bing, Megan, Bertrand, Laura, Gross, Brett P, Makkouk, Amani, Starenki, Dmytro, Farag, Kristine I, Sorge, Robert E, Brown, James A, Gordetsky, Jennifer, Yasin, Hesham, Garje, Rohan, Nandagopal, Lakshminarayanan, Weiner, George J, Lubaroff, David M, Arend, Rebecca C, Li, Peng, Zakharia, Yousef, Yang, Eddy, Salem, Aliasger K, Nepple, Kenneth, Marquez-Lago, Tatiana T, Norian, Lyse A
Formato: Artigo
Idioma:Inglês
Publicado em: BMJ Publishing Group 2020
Assuntos:
Clinical/Translational Cancer Immunotherapy
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7757487/
https://ncbi.nlm.nih.gov/pubmed/33427691
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/jitc-2020-000725
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados